JPRN-UMIN000002016已完成2 期
Multi-Center Phase II Study on Efficacy of High-Slip Skin Care Pad for Hand-Foot Skin Reaction Caused by Sorafenib in Patients with Renal Cell Carcinoma - Study on Efficacy of High-Slip Skin Care Pad for HFSR by Sorafenib in Patients with Renal Cell Carcinoma
Japanese Society of Renal Cancer (JSRC)0 个研究点目标入组 100 人开始时间: 2009年5月29日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients undergoing combination therapy with cytokine therapy, chemotherapy, or molecularly targeted therapy 2) Patients who have used other molecularly targeted drug therapy 3) Patients in whom the underlying disease is a generalized dermatological disease 4) Patients with Grade 2 or higher HFSR on the hands 5) Patients with Grade 3 or higher adverse events other than HFSR 6) Patients with previously confirmed sorafenib-induced HFSR 7) Patients determined to be unsuitable by investigators 8) Patients who may otherwise compromise patient safety in the conduct of the trial or who may compromise protocol compliance
研究者
相似试验
招募中
1 期
Clinical Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing SarcomaMedDRA version: 20.0Level: PTClassification code 10015560Term: Ewing's sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ewing SarcomaEUCTR2023-000169-14-ITFondazione Santobono Pausilipon ONLUS60
已完成
不适用
A clinical study to evaluate the efficacy of high-blood pressure by continuous ingestion of food containing plant-derived ingredients. ( SME-2021-01-FOSHUS)JPRN-UMIN000044352SUNTORY MONOZUKURI EXPERT LIMITED120
进行中（未招募）
不适用
A multicentre phase II study of the efficacy and safety of lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) or monosomy 5. - Lenalidomide in high-risk myeloid disease with 5qEUCTR2007-000450-31-SEThe Nordic MDS group50
进行中（未招募）
不适用
A multicentre phase II study of the efficacy and safety of lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) or monosomy 5. - Lenalidomide in high-risk myeloid disease with 5qHigh risk Myelodysplastic Syndrome (IPSS Int-2 or High) or Acute Myeloid Leukemia with a karyotype including del(5q) or monosomy 5MedDRA version: 9.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeMedDRA version: 9.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaEUCTR2007-000450-31-DKThe Nordic MDS group50
招募中
2 期
A phase II multicenter study comparing the efficacy of the oral angiogenesis inhibitor nintedanib with the intravenous cytotoxic compound ifosfamide for treatment of patients with advanced metastatic soft tissue sarcoma after failure of systemic non-oxazaphosporine-based first line chemotherapy for inoperable disease ANITASoft tissue sarcoma10072990CancerNL-OMON50681European Organisation for Research in Treatment of Cancer (EORTC)22